Immunohistochemical Demonstration of Enzymatically Modified Human LDL and Its Colocalization With the Terminal Complement Complex in the Early Atherosclerotic Lesion

From the Institute of Pathology, University of Düsseldorf, Düsseldorf (M.T., H.E.G.); the Institute of Medical Microbiology, University of Mainz, Hochhaus am Augustus-platz, Mainz (M.K., M.M., B.D., S.B.); the Department of Internal Medicine, University of Ulm, Ulm (J.T.); and Chiron Behring, Marburg (J.H.).

Abstract—Treatment of low density lipoprotein (LDL) with degrading enzymes transforms the molecule to a moiety that is micromorphologically indistinguishable from lipoproteinaceous particles that are present in atherosclerotic plaques, and enzymatically modified LDL (E-LDL), but not oxidized LDL (ox-LDL), spontaneously activates the alternative complement pathway, as do lesion lipoprotein derivatives. Furthermore, because E-LDL is a potent inducer of macrophage foam cell formation, we propose that enzymatic degradation may be the key process that renders LDL atherogenic. In this article, we report the production of two murine monoclonal antibodies recognizing cryptic epitopes in human apolipoprotein B that become exposed after enzymatic attack on LDL. One antibody reacted with LDL after single treatment with trypsin, whereas recognition by the second antibody required combined treatment of LDL with trypsin and cholesterol esterase. In ELISAs, both antibodies reacted with E-LDL produced in vitro and with lesion complement activator derived from human atherosclerotic plaques, but they were unreactive with native LDL or ox-LDL. The antibodies stained E-LDL, but not native LDL or ox-LDL, that had been artificially injected into arterial vessel walls. With the use of these antibodies, we have demonstrated that early human atherosclerotic coronary lesions obtained at autopsy as well as lesions examined in freshly explanted hearts always contain extensive extracellular deposits of E-LDL. Terminal complement complexes, detected with a monoclonal antibody specific for a C5b-9 neoepitope, colocalized with E-LDL within the intima, which is compatible with the proposal that subendothelially deposited LDL is enzymatically transformed to a complement activator at the earliest stages in lesion development.

Key Words: atherosclerosis • LDL • complement activation • enzymatic degradation • immunohistochemistry

This article has been cited by other articles:

				L. Zhang, Y. Liu, X. T. Lu, Y. L. Wu, C. Zhang, X. P. Ji, R. Wang, C. X. Liu, J. B. Feng, H. Jiang, et al. Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H2004 - H2014. [Abstract] [Full Text] [PDF]

				V. W.Y. Leung, S. Yun, M. Botto, J. C. Mason, T. H. Malik, W. Song, D. Paixao-Cavalcante, M. C. Pickering, J. J. Boyle, and D. O. Haskard Decay-Accelerating Factor Suppresses Complement C3 Activation and Retards Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice Am. J. Pathol., October 1, 2009; 175(4): 1757 - 1767. [Abstract] [Full Text] [PDF]

				Y. Nakashima, T. N. Wight, and K. Sueishi Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans Cardiovasc Res, July 1, 2008; 79(1): 14 - 23. [Abstract] [Full Text] [PDF]

				E. Shagdarsuren, K. Bidzhekov, Y. Djalali-Talab, E. A. Liehn, M. Hristov, R. A. Matthijsen, W. A. Buurman, A. Zernecke, and C. Weber C1-Esterase Inhibitor Protects Against Neointima Formation After Arterial Injury in Atherosclerosis-Prone Mice Circulation, January 1, 2008; 117(1): 70 - 78. [Abstract] [Full Text] [PDF]

				C. A. Gleissner, N. Leitinger, and K. Ley Effects of Native and Modified Low-Density Lipoproteins on Monocyte Recruitment in Atherosclerosis Hypertension, August 1, 2007; 50(2): 276 - 283. [Full Text] [PDF]

				Y. Nakashima, H. Fujii, S. Sumiyoshi, T. N. Wight, and K. Sueishi Early Human Atherosclerosis: Accumulation of Lipid and Proteoglycans in Intimal Thickenings Followed by Macrophage Infiltration Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1159 - 1165. [Abstract] [Full Text] [PDF]

				D. R. Anderson, J. M. Tsutsui, F. Xie, S. J. Radio, and T. R. Porter The role of complement in the adherence of microbubbles to dysfunctional arterial endothelium and atherosclerotic plaque Cardiovasc Res, February 1, 2007; 73(3): 597 - 606. [Abstract] [Full Text] [PDF]

				A. Schepers, M.R. de Vries, C.J. van Leuven, J.M. Grimbergen, V.M. Holers, M.R. Daha, J.H. van Bockel, and P.H.A. Quax Inhibition of Complement Component C3 Reduces Vein Graft Atherosclerosis in Apolipoprotein E3-Leiden Transgenic Mice Circulation, December 19, 2006; 114(25): 2831 - 2838. [Abstract] [Full Text] [PDF]

				J. K. Hakala, K. A. Lindstedt, P. T. Kovanen, and M. O. Pentikainen Low-Density Lipoprotein Modified by Macrophage-Derived Lysosomal Hydrolases Induces Expression and Secretion of IL-8 Via p38 MAPK and NF-{kappa}B by Human Monocyte-Derived Macrophages Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2504 - 2509. [Abstract] [Full Text] [PDF]

				M. Torzewski, P. Suriyaphol, K. Paprotka, L. Spath, V. Ochsenhirt, A. Schmitt, S.-R. Han, M. Husmann, V. B. Gerl, S. Bhakdi, et al. Enzymatic Modification of Low-Density Lipoprotein in the Arterial Wall: A New Role for Plasmin and Matrix Metalloproteinases in Atherogenesis Arterioscler Thromb Vasc Biol, November 1, 2004; 24(11): 2130 - 2136. [Abstract] [Full Text] [PDF]

				L. Persson, J. Boren, A.-K. L. Robertson, V. Wallenius, G. K. Hansson, and M. Pekna Lack of Complement Factor C3, but Not Factor B, Increases Hyperlipidemia and Atherosclerosis in Apolipoprotein E-/- Low-Density Lipoprotein Receptor-/- Mice Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1062 - 1067. [Abstract] [Full Text] [PDF]

				S. Bhakdi, M. Torzewski, K. Paprotka, S. Schmitt, H. Barsoom, P. Suriyaphol, S.-R. Han, K. J. Lackner, and M. Husmann Possible Protective Role for C-Reactive Protein in Atherogenesis: Complement Activation by Modified Lipoproteins Halts Before Detrimental Terminal Sequence Circulation, April 20, 2004; 109(15): 1870 - 1876. [Abstract] [Full Text] [PDF]

				S. B. Schwedler, F. Guderian, J. Dammrich, L. A. Potempa, and C. Wanner Tubular staining of modified C-reactive protein in diabetic chronic kidney disease Nephrol. Dial. Transplant., November 1, 2003; 18(11): 2300 - 2307. [Abstract] [Full Text] [PDF]

				H. Rus and F. Niculescu Association of Complement Inhibitors With Connective Tissue Matrix in Atherosclerotic Lesions Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1478 - 1478. [Full Text] [PDF]

				J. K. Hakala, R. Oksjoki, P. Laine, H. Du, G. A. Grabowski, P. T. Kovanen, and M. O. Pentikainen Lysosomal Enzymes Are Released From Cultured Human Macrophages, Hydrolyze LDL In Vitro, and Are Present Extracellularly in Human Atherosclerotic Lesions Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1430 - 1436. [Abstract] [Full Text] [PDF]

				S.-R. Han, A. Momeni, K. Strach, P. Suriyaphol, D. Fenske, K. Paprotka, S. I. Hashimoto, M. Torzewski, S. Bhakdi, and M. Husmann Enzymatically Modified LDL Induces Cathepsin H in Human Monocytes: Potential Relevance in Early Atherogenesis Arterioscler Thromb Vasc Biol, April 1, 2003; 23(4): 661 - 667. [Abstract] [Full Text] [PDF]

				R. Oksjoki, H. Jarva, P. T. Kovanen, P. Laine, S. Meri, and M. O. Pentikainen Association Between Complement Factor H and Proteoglycans in Early Human Coronary Atherosclerotic Lesions: Implications for Local Regulation of Complement Activation Arterioscler Thromb Vasc Biol, April 1, 2003; 23(4): 630 - 636. [Abstract] [Full Text] [PDF]

				P. Suriyaphol, D. Fenske, U. Zahringer, S.-R. Han, S. Bhakdi, and M. Husmann Enzymatically Modified Nonoxidized Low-Density Lipoprotein Induces Interleukin-8 in Human Endothelial Cells: Role of Free Fatty Acids Circulation, November 12, 2002; 106(20): 2581 - 2587. [Abstract] [Full Text] [PDF]

				J. C. Mason, Z. Ahmed, R. Mankoff, E. A. Lidington, S. Ahmad, V. Bhatia, A. Kinderlerer, A. M. Randi, and D. O. Haskard Statin-Induced Expression of Decay-Accelerating Factor Protects Vascular Endothelium Against Complement-Mediated Injury Circ. Res., October 18, 2002; 91(8): 696 - 703. [Abstract] [Full Text] [PDF]

				M.-K. Chang, C. J. Binder, M. Torzewski, and J. L. Witztum From the Cover: C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids PNAS, October 1, 2002; 99(20): 13043 - 13048. [Abstract] [Full Text] [PDF]

				C. Buono, C. E. Come, J. L. Witztum, G. F. Maguire, P. W. Connelly, M. Carroll, and A. H. Lichtman Influence of C3 Deficiency on Atherosclerosis Circulation, June 25, 2002; 105(25): 3025 - 3031. [Abstract] [Full Text] [PDF]

				D. Kielar, W. Dietmaier, T. Langmann, C. Aslanidis, M. Probst, M. Naruszewicz, and G. Schmitz Rapid Quantification of Human ABCA1 mRNA in Various Cell Types and Tissues by Real-Time Reverse Transcription-PCR Clin. Chem., December 1, 2001; 47(12): 2089 - 2097. [Abstract] [Full Text] [PDF]

				H.-A. Lehr, T. A. Sagban, C. Ihling, U. Zahringer, K.-D. Hungerer, M. Blumrich, K. Reifenberg, and S. Bhakdi Immunopathogenesis of Atherosclerosis: Endotoxin Accelerates Atherosclerosis in Rabbits on Hypercholesterolemic Diet Circulation, August 21, 2001; 104(8): 914 - 920. [Abstract] [Full Text] [PDF]

				K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer Complement Components, but Not Complement Inhibitors, Are Upregulated in Atherosclerotic Plaques Arterioscler Thromb Vasc Biol, July 1, 2001; 21(7): 1214 - 1219. [Abstract] [Full Text] [PDF]

				M. Kapinsky, M. Torzewski, C. Buchler, C. Q. Duong, G. Rothe, and G. Schmitz Enzymatically Degraded LDL Preferentially Binds to CD14high CD16+ Monocytes and Induces Foam Cell Formation Mediated Only in Part by the Class B Scavenger-Receptor CD36 Arterioscler Thromb Vasc Biol, June 1, 2001; 21(6): 1004 - 1010. [Abstract] [Full Text] [PDF]

				K. Yasojima, C. Schwab, E. G. McGeer, and P. L. McGeer Generation of C-Reactive Protein and Complement Components in Atherosclerotic Plaques Am. J. Pathol., March 1, 2001; 158(3): 1039 - 1051. [Abstract] [Full Text] [PDF]

				K. Öörni, M. O. Pentikäinen, M. Ala-Korpela, and P. T. Kovanen Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions J. Lipid Res., November 1, 2000; 41(11): 1703 - 1714. [Abstract] [Full Text]

				J. Kramer, P. Harcos, Z. Prohaszka, L. Horvath, I. Karadi, M. Singh, A. Csaszar, L. Romics, and G. Fust Frequencies of Certain Complement Protein Alleles and Serum Levels of Anti-Heat-Shock Protein Antibodies in Cerebrovascular Diseases Stroke, November 1, 2000; 31(11): 2648 - 2652. [Abstract] [Full Text] [PDF]

				M. Torzewski, C. Rist, R. F. Mortensen, T. P. Zwaka, M. Bienek, J. Waltenberger, W. Koenig, G. Schmitz, V. Hombach, and J. Torzewski C-Reactive Protein in the Arterial Intima : Role of C-Reactive Protein Receptor-Dependent Monocyte Recruitment in Atherogenesis Arterioscler Thromb Vasc Biol, September 1, 2000; 20(9): 2094 - 2099. [Abstract] [Full Text] [PDF]

				M. Klouche, S. Rose-John, W. Schmiedt, and S. Bhakdi Enzymatically Degraded, Nonoxidized LDL Induces Human Vascular Smooth Muscle Cell Activation, Foam Cell Transformation, and Proliferation Circulation, April 18, 2000; 101(15): 1799 - 1805. [Abstract] [Full Text] [PDF]

				C. Urbich, M. Fritzenwanger, A. M. Zeiher, and S. Dimmeler Laminar Shear Stress Upregulates the Complement-Inhibitory Protein Clusterin : A Novel Potent Defense Mechanism Against Complement-Induced Endothelial Cell Activation Circulation, February 1, 2000; 101(4): 352 - 355. [Abstract] [Full Text] [PDF]

				C. D. Collard, A. Agah, W. Reenstra, J. Buras, and G. L. Stahl Endothelial Nuclear Factor-{kappa}B Translocation and Vascular Cell Adhesion Molecule-1 Induction by Complement : Inhibition With Anti-Human C5 Therapy or cGMP Analogues Arterioscler Thromb Vasc Biol, November 1, 1999; 19(11): 2623 - 2629. [Abstract] [Full Text] [PDF]

				S. Bhakdi, M. Torzewski, M. Klouche, and M. Hemmes Complement and Atherogenesis : Binding of CRP to Degraded, Nonoxidized LDL Enhances Complement Activation Arterioscler Thromb Vasc Biol, October 1, 1999; 19(10): 2348 - 2354. [Abstract] [Full Text] [PDF]

				G. A. Ewy Antioxidant Therapy for Coronary Artery Disease: Don't Paint the Walls Without Treating the Termites! Arch Intern Med, June 28, 1999; 159(12): 1279 - 1280. [Full Text] [PDF]

				M. Klouche, A. E. May, M. Hemmes, M. Meßner, S. M. Kanse, K. T. Preissner, and S. Bhakdi Enzymatically Modified, Nonoxidized LDL Induces Selective Adhesion and Transmigration of Monocytes and T-Lymphocytes Through Human Endothelial Cell Monolayers Arterioscler Thromb Vasc Biol, March 1, 1999; 19(3): 784 - 793. [Abstract] [Full Text] [PDF]

				W. Schmiedt, R. Kinscherf, H.-P. Deigner, H. Kamencic, O. Nauen, J. Kilo, H. Oelert, J. Metz, and S. Bhakdi Complement C6 Deficiency Protects Against Diet-Induced Atherosclerosis in Rabbits Arterioscler Thromb Vasc Biol, November 1, 1998; 18(11): 1790 - 1795. [Abstract] [Full Text] [PDF]

				M. Klouche, S. Gottschling, V. Gerl, W. Hell, M. Husmann, B. Dorweiler, M. Messner, and S. Bhakdi Atherogenic Properties of Enzymatically Degraded LDL : Selective Induction of MCP-1 and Cytotoxic Effects on Human Macrophages Arterioscler Thromb Vasc Biol, September 1, 1998; 18(9): 1376 - 1385. [Abstract] [Full Text] [PDF]

				J. Torzewski, M. Torzewski, D. E. Bowyer, M. Frohlich, W. Koenig, J. Waltenberger, C. Fitzsimmons, and V. Hombach C-Reactive Protein Frequently Colocalizes With the Terminal Complement Complex in the Intima of Early Atherosclerotic Lesions of Human Coronary Arteries Arterioscler Thromb Vasc Biol, September 1, 1998; 18(9): 1386 - 1392. [Abstract] [Full Text] [PDF]

				J. C. Mason, E. A. Lidington, S. R. Ahmad, and D. O. Haskard bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction Am J Physiol Cell Physiol, March 1, 2002; 282(3): C578 - C587. [Abstract] [Full Text] [PDF]